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Abstract 
Purpose.  To implement an evidence-based hyperlipidemia guideline for statin therapy use with 
diabetic patients. Background.  In the United States, cardiovascular disease (CVD) continues to 
be the leading cause of mortality and morbidity for women and men with diabetes. Dyslipidemia 
is a modifiable risk factor for CVD and one of the leading drivers behind the development of 
coronary artery disease. In 2014, the American Diabetes Association issued a new 
recommendation guideline for using statins as a primary intervention for CVD in patients aged 
40–75 with diabetes. Despite advances in prevention and treatment guidelines, the American 
College of Cardiology and ADA have identified a substantial gap in hyperlipidemia guideline 
implementation across clinical settings. Methods.  Patients with diabetes were identified and 
assigned a statin dose based on their risk factors for atherosclerotic CVD. Patients with a history 
of clinical atherosclerotic CVD were initiated on a high-dose statin therapy, whereas those with 
no history of CVD were initiated on a moderate-dose statin therapy. Follow-up was conducted at 
6 weeks. Outcomes. Out of 122 diabetic patients, 61 (46.5%) were newly started on a statin, 33 
(27%) had their statin corrected to the proper dose, 28 (23%) were on the proper statin dose 
already, and 8 (3.5%) were ineligible for a statin. All patients (100%) taking a statin tolerated 
their dose and experienced no adverse effects. Implications for Practice. Bridging the gap 
between research and practice can be successful with careful implementation of a system that 
can be followed to improve outcomes.  
Keywords: diabetes, cardiovascular disease, statin therapy. 
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 Diabetes mellitus (hereafter referred to as diabetes) is a chronic health condition that 
occurs when the body produces little to no insulin. Diabetes develops from a combination of 
genetic and environmental factors (Martín-Timón, Sevillano-Collantes, Segura-Galindo, & Del 
Cañizo-Gómez, 2014). An estimated 366 million people worldwide were reported to have 
diabetes in 2011, although half were undiagnosed; the total figure is expected to rise to 552 
million by 2030 (Martín-Timón et al., 2014). Approximately 25.8 million people in the United 
States are living with diabetes (Thapa et al., 2015). As the prevalence of the disease increases, so 
will the proportion of older adults (i.e., ≥ 65 years) with the condition (Thapa et al., 2015). 
Diabetes is a well-established risk factor for cardiovascular disease (CVD). Compared with 
individuals without diabetes, patients with Type 2 diabetes are twice as likely to suffer from 
cardiovascular morbidity and mortality and are disproportionately affected by CVD. The Centers 
for Disease Control and Prevention (2017) reported that CVD is the leading cause of death for 
men and women with diabetes. 
  In 2013, the American College of Cardiology (ACC) and American Heart Association 
jointly issued a new recommendation for treatment using 3-hydroxy-3-methylglutaryl-coenzyme, 
a reductase inhibitor otherwise known as a statin, as primary prevention of atherosclerotic CVD 
for people with diabetes between 40 and 75 years old. The 2017 American Diabetes Association 
(ADA) guidelines for statin therapy are as follows (see Appendix A for details): 1) individuals 
age 40 and younger: no statin recommendation; 2) patients aged 40–75 with diabetes and no risk 
factors for atherosclerotic CVD: moderate statin therapy in addition to lifestyle modifications; 3) 
patients aged 40–75 with diabetes and risk factors for atherosclerotic CVD: moderate or high-
intensity statin therapy in addition to lifestyle modifications (ADA, 2017). Lifestyle 
modifications include weight management; reducing consumption of saturated fat, trans fats, and 
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cholesterol; increasing dietary intake of omega-3 fatty acids and viscous fiber; and increased 
activity. These lifestyle changes can help improve lipid profiles in diabetic patients. 
 Apart from lifestyle changes, statins have been identified as the most effective first-line 
drugs for lowering cholesterol and reducing cardiovascular risk (Page, Sanfilippo, Geelhoed, 
Briffa, & Hobbs, 2012). The Food and Drug Administration has approved several types of 
statins, each of which works differently to lower cholesterol by blocking the liver’s production of 
HMG CoA enzyme used in making cholesterol. Commonly prescribed statins include Lovastatin 
(Mevacor), Atorvastatin (Lipitor), Simvastatin (Zocor), Pravastatin (Livalo), Fluvastatin 
(Lescol), and Rosuvastatin (Crestor); see Appendix B for dosage information.  
Statement of the Problem 
Several clinical studies have demonstrated the benefits of statin therapy in the primary 
and secondary prevention of atherosclerotic CVD and even death in diabetic patients. The ADA 
(2017) conducted a meta-analysis of data from 18,000 patients with diabetes based on 14 
randomized trials of statin therapy. Results showed that the all-cause mortality rate declined by 
9% and the vascular mortality rate declined by 13% when LDL cholesterol was reduced by 
39mg/dL. According to Kiramijyan et al. (2013), the most common cause of death in diabetic 
patients is coronary artery disease; approximately 70% of diabetic patients die of CVD and are 
twice as likely to suffer from related conditions including myocardial infarction, angina pectoris, 
stroke, and cardiac death compared to the general population. Of individuals living with diabetes 
in the U.S., 735,000 have had a heart attack (525,000 first-time episodes and 210,000 recurrent) 
(CDC, 2017). Modifiable risk factors for CVD include hypertension, dyslipidemia, and obesity; 
non-modifiable risk factors include diabetes, age, ethnicity, and family history of heart disease.  
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Background and Significance  
Research has led to the adaptation and implementation of recommended hyperlipidemia 
guidelines in the use of statin therapy in diabetic patients. Studies have shown that statin therapy 
substantially reduces the risk of a future cardiovascular event in patients with Type 2 diabetes 
regardless of their history of heart disease. The initiation of statin therapy is primarily based on 
risk factors rather than cholesterol levels. Page et al. (2012) reported that approximately 5,355 
major cardiovascular events, including 1,456 fatal events, could have been prevented in diabetes 
patients aged 60–79 if statin therapy had been initiated. Thapa et al. (2015) noted significant 
improvements in lipid management and fewer cardiovascular events in diabetic patients given 
statin therapy. Thapa et al. (2015) also found that healthcare providers tended to underutilize 
guidelines regarding the use of statin therapy to all diabetic patients irrespective of CVD 
diagnosis; specifically, healthcare providers were more likely to provide statin therapy to 
diabetes patients with CVD than to those without.      
 Pokharel et al. (2016) reported that some healthcare providers manage diabetic patients 
and CVD differently from those without CVD even though both groups have the same risk 
factors. Hence, a gap remains between current recommendation guidelines in statin use and their 
implementation in clinical practice. National efforts to adopt guidelines for the use of statin 
therapy in all diabetic patients must therefore be intensified. Pokharel et al. (2016) urged 
healthcare providers and patients to discuss prevention strategies related to heart attack, stroke, 
and other risk factors at every opportunity. Eliminating barriers, such as inadequate medical 
records, and creating decision support tools (e.g., alerts and reminders, clinical guidelines, and 
focused patient data report dashboards) may help improve recommended guidelines on statin use 
IMPLEMENTING HYPERLIPIDEMIA STATIN USE GUIDELINE 12 
 
to enhance risk reduction along with clinical performance and patient outcomes (Pokharel et al., 
2016). 
Assessment 
The site for this research project was a small, independently owned family practice clinic 
in Kingwood, TX. Dr. A. J. is a primary care/family medicine doctor and owns the clinic with 
her spouse, a nephrologist. Dr. A. J. completed her medical education in India and has been 
practicing for 32 years. The clinic accepts patients from ages 16 to 65 and older. The youngest 
patient at the clinic is 16, and the oldest is 93. Major patient categories are presented in Table 1; 
patient ethnicities are listed in Table 2. With regard to education level, patients hold a high 
school diploma on average. Some Hispanic patients speak little to no English.  
  The clinic is approximately 2,000 square feet and includes a waiting room, three triage 
rooms, two physician offices, one staff lounge/break room, a secretarial space, and a small staff 
workstation. The clinic accepts all types of insurance as well as uninsured and self-pay patients. 
Approximately 10 to 25 patients are seen in the clinic per day (10–15 current patients and 5–10 
new). The clinic sees 30 to 50 current patients per week (100–150/month) and 20 to 25 new 
patients (30–50/month) within the same time frame. The clinic provides primary care, preventive 
services, and acute illness and chronic disease management. The clinic staff includes a physician, 
a secretary, and a medical assistant who also acts as the office manager. Dr. J.A.’s husband, a 
nephrologist, co-owns the practice and has scheduled appointments throughout the week during 
which he sees patients with acute or chronic kidney diseases. Patients are required to schedule an 
appointment before coming to see a physician. The clinic staff also requires that appointments be 
made to discuss abnormal lab or diagnostic results and for follow-up visits. The secretary is the 
only bilingual staff member and serves as an interpreter for the clinic’s non-English-speaking 
Hispanic population.  
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Table 1 
Clinic Population in 2017 
Patient 
status 
 # of patients 
(N = 6,625) 
Percent (%) 
Established 4,100 62 
New 2,525 38 
Diabetics 1,720 26 
Diabetics 
with h/o 
CVD 
and/or 
HLD 
1,235 19 
Table 2 
Ethnicities of Clinic Patients 
Ethnicity 
 # of patients 
(%) 
Non-Hispanic 
whites 
40 
African 
American 
20 
Hispanic/Latino 30 
Other 10 
Organization’s Readiness for Change 
The clinic provides high-quality care to its patient population as reported in patient 
satisfaction surveys (average score of 4.4 out of 5). Patients were reportedly satisfied with Dr. A. 
J.’s care. They generally felt their diagnoses and medications were properly managed and 
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reported positive post-treatment health outcomes. However, recent guidelines regarding the 
recommendation of statin therapy to all diabetic patients with or without a history of 
atherosclerotic CVD is not being implemented at the clinic. According to the ACC (2016), two 
out of five individuals with diabetes could benefit from statin therapy in lowering their risk for a 
cardiovascular event, as patients with Type 2 diabetes are at high risk for atherosclerotic CVD 
and stroke (ADA, 2017). These patients are also considered to be at equal risk of a future 
cardiovascular event as individuals with a history of CVD (Thapa et al., 2015). Therefore, it is 
important to control CVD risk factors such as elevated cholesterol levels.  
Routine screening for atherosclerotic CVD risk and providing patient education around 
prevention are similarly important (ADA, 2017). Effective counseling and medication-based 
education can help patients understand their increased risks of atherosclerotic CVD and high 
LDL cholesterol levels. Such measures may help to improve patient outcomes at the clinic. 
Optimal care of patients with Type 2 diabetes depends on providers and the quality of care they 
offer patients, especially regarding prevention of future cardiovascular events and, by extension, 
high morbidity and mortality (ADA, 2017). As noted, the ADA guideline around the 
recommended use of statin therapy was not being implemented with all diabetic patients 
(especially those with no history of CVD) at Dr. A. J.’s practice. The clinic also had no 
electronic medical record alert system through which to provide guideline reminders. Upon 
meeting with Dr. A. J. and discussing the ADA’s recommended clinical guideline, the clinic 
appeared ready to adopt a change in practice. 
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Project Identification 
Purpose 
  The purpose of this project is to initiate an evidence-based quality improvement project 
concerning the implementation of an ADA hyperlipidemia treatment guideline for the use of 
statin therapy on diabetic patients. 
Objectives 
1. To implement the APA’s hyperlipidemia clinical guideline. 
2. To educate the physician and clinic staff of the guideline and scope of the DNP project. 
3. By April 2018, 100% of identified diabetic patients in Dr. A. J.’s clinic will be educated 
about and given appropriate supplementary material on the benefits of statin therapy. 
4. By April 2018, at least 90% of diabetic patients in Dr. A. J.’s clinic will begin statin 
therapy and adhere to the treatment guideline. 
Anticipated Outcomes 
1. 100% of the physician and clinic staff will be educated on the hyperlipidemia guideline 
2. 100% of the clinic’s diabetic patients will be educated on the guideline. 
3. 90% of patients will begin statin therapy and be monitored appropriately. 
Summary and Strength of the Evidence 
According to the U.S. Preventive Service Task Force (2016), coronary artery disease is 
responsible for about one-fifth of deaths in adults aged 45–65 and one-fourth of deaths in adults 
aged 65 and older. The benefits of statin use in reducing CVD-related morbidity and mortality 
have been demonstrated in several studies (USPSTF, 2016). A study of 19 randomized trials 
totaling 71,344 participants evaluated the effects of statin use in adults with diabetes with no 
history of CVD events; results showed statin use to be statistically associated with a reduced 
incidence of CVD, myocardial infarction, and stroke (USPSTF, 2016). A primary prevention 
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trial on statin use, JUPITER, found that statin allocation was associated with a 39% reduction in 
major CVD events such as heart attack or ischemia, a 36% reduction in venous 
thromboembolism, a 17% reduction in total mortality, and avoidance of 134 vascular events or 
deaths (Ridker, Pradhan, MacFadyen, Libby, & Glynn, 2012). The JUPITER primary prevention 
trial concluded that the benefits of statin therapy exceeded the risks associated with diabetes and 
CVD (Ridker et al., 2012). 
Method 
Project Intervention 
 The setting of the project was Dr. A. J.’s family care clinic, a small, independently owned 
family practice located in southeastern TX. A statin therapy guideline was implemented in all 
diabetic patients between 40 and 75 years old. Data collected from patients’ electronic medical 
records (EMRs) included demographic information such as age, gender, ethnicity, insurance 
type, education level, current medications, and medical history and laboratory test results (see 
Appendix B). The physician and clinic staff were instructed on the evidence-based 
hyperlipidemia clinical guideline on statin use before implementing it. They were also educated 
on the algorithm (Appendix D) that explained the steps and assigned roles of each staff. The 
algorithm was posted by each computer in the nurses’ station for reference. Educational 
brochures were created to help familiarize the patient population with the benefits of using statin 
therapy and its relationship with cardiovascular risk factors. The clinic’s secretary, who is also a 
medical assistant, served as a Spanish interpreter to educate non-English-speaking diabetic 
patients and their caregivers.  
 When patients called for an appointment, the secretary verified whether they were 
diabetic; if so, these patients’ appointment times were coded in blue, and their EMRs were 
flagged once statin therapy was initiated to ensure appropriate evaluation of their treatment plan. 
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On the day of patients’ appointments, during the triage process, the medical assistant verified 
their medication to determine whether patients were on a statin therapy and documented each 
patient’s response under the Assessment tab in his/her EMR. Patients with diabetes were also 
given a brochure educating them on the benefits of statin therapy. The physician assessed 
patients by reviewing their lab tests at baseline to verify whether they were eligible to receive a 
statin, ensure they were assigned the correct dose, and began statin therapy with an emphasis on 
adhering to the treatment guideline. Each patient’s liver function test was reviewed at baseline 
and monitored during a 4-week follow-up plan. The statin was dosed based on the patient’s 
atherosclerotic CVD risk. Patients with a history of clinical atherosclerotic CVD were initiated 
on a high-dose statin therapy, whereas those with no history of CVD were initiated on a 
moderate-dose statin therapy. Dr. A. J. conducted follow-up appointments at 4 weeks.  
Organizational Barriers 
Hispanics comprised approximately 50% of the clinic’s diabetic patient population. 
African Americans constituted about 40%, and the remaining 10% was a mix of other races. 
Most Hispanic patients spoke little to no English and were often accompanied by a family 
member to translate. Although the clinic’s medical assistant interpreted for Spanish-speaking 
clientele, this could be viewed as a barrier because her primary role was overseeing the front 
office. She therefore managed various tasks, such as answering phone calls, scheduling 
appointments, verifying insurance, sending appointment reminders, and checking patients in and 
out. Being called into a triage room to interpret for a patient could be disruptive when other tasks 
required equal attention. The clinic is actively looking to hire an additional bilingual staff 
member to assist its Spanish-speaking population. The clinic’s insufficient staff posed another 
barrier; considering that the two staff members (i.e., medical assistant and secretary) were 
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overburdened with responsibilities, continued implementation of this clinical guideline could 
eventually be overlooked.  
 Staff time may also present a barrier to ongoing implementation of this project. Although 
the clinical practice is small, time constraints due to understaffing could lead to tasks remaining 
unfinished, such as following up on appointments, referrals, and laboratory/diagnostic results. 
Staff rarely clock out on time, often staying 30 minutes to an hour after their shift to complete 
outstanding work. Another potential barrier is the average education level of the patient 
population (i.e., high school) and corresponding eighth grade comprehension in many cases.  In 
addition, no written or verbal medication education was being given to patients, yet medication 
information and counseling are essential parts of patient care and should be provided during 
patient–provider interaction at each visit office visit (Yi et al., 2015). To promote effective 
medication compliance, providers must tailor education to each patients’ needs, level of 
understanding, and preferred format (e.g., verbal, written, or both) (Yi et al., 2015).  
            The use of unskilled staff may further explain why continued patient compliance to 
medication regimens could pose an organizational barrier. The clinic is staffed with two medical 
assistants with a high school education; educating patients about medications is beyond their 
scope of practice, as is monitoring patients’ lab values and medication adherence. According to 
Barra (2011), a medical assistant lacks the educational and clinical background that a nurse 
possesses from years of education and continuous practice; thus, medical assistants are generally 
unprepared to adequately interpret lab results and educate patients about their medications. Barra 
(2011) emphasized that patient safety and well-being can be at risk when there is a lack of 
competent, licensed staff to render high-quality patient services. 
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A lack of contact time between provider and patients was another barrier to effective 
continuation of this project. Dr. A. J.’s family care practice is a prime example of a fast-paced 
healthcare system; it is a small, busy clinic with only one provider, and effective patient 
monitoring can be easily overlooked when trying to move through patients quickly. According to 
Yi et al., (2015), brief contact between healthcare providers and patient is a barrier to effective 
medication adherence. Continued compliance with statin therapy could therefore prove 
challenging, as patients required substantial reinforcement during each office visit to ensure 
ongoing adherence to the statin regimen.  
Facilitators 
The physician and staff voiced their willingness to assist with and support the 
implementation of the ADA’s hyperlipidemia clinical guideline. The student (i.e., project 
researcher) was equally hopeful about the project. A hyperlipidemia guideline is urgently needed 
and should prove beneficial to all patients with diabetes. The clinic’s EHR system also allowed 
patients’ records to be color-coded and flagged for simple patient identification, which facilitated 
follow-up for the duration of the project.  
Ethical Implications 
No ethical concerns were anticipated regarding the implementation of the hyperlipidemia 
guideline. 
Results 
A total of 149 diabetic patients visited Dr. A. J.’s clinic from January 21, 2018 to April 6, 
2018; see Table 3 for patient characteristics and corresponding data. Appendix C outlines the 
patient data collected each week. The DNP student reviewed each patient’s EMR weekly to 
ensure the hyperlipidemia guideline was followed. Patients’ pre-intervention satisfaction scores 
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revealed that 80% of patients believed that their diagnoses and medications were not being well 
managed at the clinic. In addition, they did not feel that their health outcomes had improved. The 
remaining 20% felt that their diagnoses and medications were properly managed by the 
physician. Patient satisfaction scores after guideline implementation demonstrated a substantial 
increase; see Table 4. Patients also reported positive health outcomes. Clinic staff now routinely 
conducts follow-up assessments. 
Table 3 
Patient Data Analysis 
Patient 
characteristics 
Total 
(N = 149) 
Percentage 
(%) 
Already on 
statin 
61 41 
Not on statin 88 50 
Ineligible for 
statin 
(contraindicated) 
8 5 
Eligible for 
statin  
80 54 
Proper statin 
dose 
28 19 
Improper statin 
dose 
33 22 
Developed side 
effects 
0 0 
Nutritional 
consult provided 
88 50 
Brochure 
provided 
113 76 
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Table 4 
Patient Satisfaction Scores 
Pre (%) Post (%) 
Not 
satisfied 
80 5 
Satisfied 20 95 
Discussion 
The purpose of this project was to implement the ADA’s hyperlipidemia clinical 
guideline on initiating statin therapy to diabetic patients regardless of their lipid level, with or 
without a history of CVD. Diabetes is a risk factor for CVD, which places diabetics at risk of 
cardiovascular events. Despite the benefits of statin therapy, studies have indicated that 
recommended treatment guidelines are often not upheld in clinical practice. Busko (2016) 
conducted a comparative study to examine statin regimens among 215,193 diabetic patients 
between 40 and 75 years old. She discovered that only 62% of diabetic patients were prescribed 
a statin or being monitored by a cardiologist for CVD-related issues when they received a statin 
prescription. Busko (2016) further noted that statin prescription varied widely among practices; 
two out of five diabetic patients without CVD were not prescribed a statin. Healthcare providers 
who manage diabetic patients should ensure these patients are receiving preventive therapies, of 
which statins are one of the most important (Busko, 2016). 
One noteworthy change over the course of this project was an increase in patient 
satisfaction scores. Patients reported that the care they received was of high quality, safe, and 
effective. They felt much more satisfied with their care and believed that the clinic genuinely 
cared about their health and well-being. A major contributing factor to the success of this project 
was the clinic staff’s willingness to implement the recommended guideline. They worked 
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effectively to ensure that each of their assigned project roles was fulfilled despite managing an 
already overwhelming workload. Staff initially struggled to complete their assigned roles, but the 
additional duties eventually became a part of their daily routine. Another point of success in this 
project was the lack of patient refusal; every patient participated and complied with guideline 
implementation. Educational brochures, careful explanation of the guideline, and patient 
education on the benefits of statin use aided in their compliance. The clinic’s EMR system also 
facilitated project completion. The clinic’s staff was able to easily implement the statin initiation 
and monitoring process because they could readily identify the diabetic population via the EMR 
system.  
Limitations 
     A limitation encountered during this project was some patients’ failure to attend their 
follow-up appointments. A 4-week follow up appointment was scheduled for each patient to 
monitor and evaluate liver function lab results; however, approximately 35% of patients did not 
keep their appointments. The clinic staff thus had to spend time placing appointment reminder 
calls and rescheduling missed appointments.  
Recommendations 
Knowledge deficits were prevalent in patients not on statin therapy at the start of this 
project. Approximately 90% of diabetic patients assessed at the clinic stated they had no 
knowledge of the guideline. As a recommendation, healthcare providers should strive to 
coordinate an ongoing diabetes self-management education class for all diabetic patients. Such 
education would help to enhance patients’ awareness and skills related to optimal self-care. 
Patients could also incorporate their personal needs and life experiences to make informed 
decisions as they face new challenges while managing diabetes. The hyperlipidemia guideline 
IMPLEMENTING HYPERLIPIDEMIA STATIN USE GUIDELINE 23 
 
also recommends lifestyle modifications as a complement to statin therapy. At the clinic, half of 
diabetic patients received a nutritional consult; in the future, all patients should be provided 
individualized medical nutritional therapy with a dietician. Nutrition-specific instructions will 
enable diabetic patients to maintain good glycemic control, lipid control, and evaluate how well 
they respond to therapy. 
Implications for Practice 
 Management of diabetic patients can be complex and involves several components 
(Richardson, Derouin, Vorderstrasse, Hipkens, & Thompson, 2014). The prevalence of diabetes 
is expected to triple by 2050, and many regions may see a sharp increase in diabetic patients as a 
result (Richardson et al., 2014). Many healthcare organizations are under pressure to apply 
innovative interventions and identify cost-effective approaches to treat this population 
(Richardson et al., 2014). Healthcare organizations have begun to integrate nurse practitioners 
(NPs) as internists to assist in improving clinical outcomes for diabetic patients, namely through 
NPs’ willingness to initiate, change, and adjust medications and offer patients alternate modes of 
treatment (Richardson et al., 2014). Especially in primary care settings, NPs have been shown to 
increase quality of care while reducing healthcare costs and improving health outcomes. In 
addition, NPs can use evidence-based clinical metrics to make immediate changes to patients’ 
treatment regimens when patients are not improving as anticipated (Richardson et al., 2014). 
 The Doctor of Nursing Practice (DNP) Essential II, “Scientific Underpinnings for 
Practice,” calls for organizational and systems leadership for quality improvement (American 
Association of Colleges of Nursing, 2006). DNPs contribute to nursing science by evaluating, 
translating, and disseminating research into practice (American Association of Colleges of 
Nursing, 2006). Key skills include the development of clinical practice guidelines, design of 
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evidence-based interventions, and evaluation of practice outcomes. Being able to lead and 
manage change within the healthcare environment is one of the most important roles of a DNP 
nurse (Stichler, 2011). DNP nurse leaders possess the skills and competencies to lead and guide 
staff members within healthcare organizations through the change process by using a thoughtful 
and deliberate approach to help ensure adoption and maintenance of change over time (Stichler, 
2011). 
This project followed the DNP essentials as described in Essential II by first undertaking 
a leadership role in identifying a patient safety issue at the clinic. A quality improvement plan 
was developed using an evidence-based clinical guideline to resolve the issue. Overall, the DNP 
student assumed a leadership role in ensuring appropriate implementation of the project. These 
contributions elicited positive change in the clinic’s operations that should continue into the 
future.  
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Appendix A 
Table A1 
Statin Therapy Indications and Intensity for Patients with Diabetes 
Risk factor Age Statin intensity 
History of atherosclerotic 
CVD 
All age groups High 
CVD risk factor 
40–75  Moderate or high 
75 and older High  
No risk factor 
40 and younger None 
40–75  Moderate 
75 and older Moderate or high 
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Table A2 
ADA Treatment Recommendations for Different Statins 
Statin 
Recommended 
daily dose (adult; 
mg) 
Low 
intensity 
(mg) 
Moderate 
intensity 
(mg) 
High 
intensity 
(mg) 
Atorvastatin 10–80 10–20 20–40 40–80 
Rosuvastatin 5–40 5 10–20 20–40 
Fluvastatin 20–80 20–40 40–80  
Lovastatin 
Immediate release 
10–80 
Extended release 
10–60 
   
Pravastatin 10–40 10–20 40–80  
Simvastatin 5–80 5–10 20–40 80 
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Appendix B 
Table B1  
Patient Demographic Data 
Characteristics 
Number of patients 
(N = 149) 
Percentage (%) 
(N = 149) 
Age 
40–55 
56–65 
66–75 
61 
38 
50 
41 
26 
33 
Gender 
Female 
Male 
 
64 
85 
 
43 
57 
Ethnicity 
Caucasian 
African American 
Hispanic 
Asian 
 
28 
52 
48 
21 
 
19 
35 
32 
14 
Insurance 
Insured 
Uninsured 
104 
45 
70 
30 
Education 
Less than high school 
High school 
Some college 
College graduate 
Masters degree and over 
 
26 
49 
23 
37 
14 
 
17 
33 
15 
25 
9 
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Appendix C 
Table C1 
Weekly Assessment Data Spreadsheet 
Week 
Diabetic 
patients 
at clinic  
(N = 149) 
On 
statin  
(n = 61) 
Not on 
statin  
(n = 
80) 
On improper 
statin dose 
(n = 33) 
On proper 
statin dose 
(n = 28) 
Total 
placed 
on 
statin  
(n = 
113) 
Ineligible 
for statin 
(n = 8) 
Wk. 1 13 4 9 2 2 11 0 
Wk. 2 11 4 7 3 1 10 0 
Wk. 3 15 7 8 4 2 11 1 
Wk. 4 18 9 9 3 4 10 2 
Wk. 5 12 5 7 4 1 11 0 
Wk. 6 19 10 9 6 2 13 2 
Wk. 7 16 4 12 2 2 14 0 
Wk. 8 18 8 10 4 2 12 2 
Wk. 9 11 4 7 1 3 8 0 
Wk. 10 16 6 10 4 2 9 1 
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Appendix D 
 
Figure 1. Algorithm. 
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